Revance(RVNC) Prnewswire·2025-02-25 10:45Core Viewpoint - A class action securities lawsuit has been filed against Revance Therapeutics, Inc. for alleged securities fraud affecting investors between February 29, 2024, and December 6, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Revance was in material breach of its Distribution Agreement with Teoxane, which granted it exclusive rights to market and distribute Teoxane's dermal fillers [2]. - The breach allegedly increased the risk of litigation and caused monetary and reputational harm to the company [2]. - The lawsuit also suggests that these issues raised the likelihood of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].